Susanna A. McColley

10.9k total citations · 4 hit papers
116 papers, 6.6k citations indexed

About

Susanna A. McColley is a scholar working on Pulmonary and Respiratory Medicine, Physiology and Epidemiology. According to data from OpenAlex, Susanna A. McColley has authored 116 papers receiving a total of 6.6k indexed citations (citations by other indexed papers that have themselves been cited), including 100 papers in Pulmonary and Respiratory Medicine, 13 papers in Physiology and 11 papers in Epidemiology. Recurrent topics in Susanna A. McColley's work include Cystic Fibrosis Research Advances (87 papers), Neonatal Respiratory Health Research (46 papers) and Tracheal and airway disorders (38 papers). Susanna A. McColley is often cited by papers focused on Cystic Fibrosis Research Advances (87 papers), Neonatal Respiratory Health Research (46 papers) and Tracheal and airway disorders (38 papers). Susanna A. McColley collaborates with scholars based in United States, United Kingdom and Germany. Susanna A. McColley's co-authors include Gerald M. Loughlin, John L. Carroll, Michael W. Konstan, Steven M. Rowe, David Waltz, Manu Jain, Michael Boyle, Carole L. Marcus, Xiaohong Huang and Alan R. Hauser and has published in prestigious journals such as New England Journal of Medicine, American Journal of Respiratory and Critical Care Medicine and PEDIATRICS.

In The Last Decade

Susanna A. McColley

112 papers receiving 6.4k citations

Hit Papers

Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Hom... 2014 2026 2018 2022 2015 2017 2014 2023 400 800 1.2k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508delCFTR
    2015 1.2k citations Claire Wainwright, Bonnie W. Ramsey et al. profile →
  2. Diagnosis of Cystic Fibrosis: Consensus Guidelines from the Cystic Fibrosis Foundation
    2017 566 citations Philip M. Farrell, Terry B. White et al. profile →
  3. A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial
    2014 336 citations Scott C. Bell, Michael W. Konstan et al. The Lancet Respiratory Medicine profile →
  4. Phase 3 Open-Label Clinical Trial of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged 2–5 Years with Cystic Fibrosis and at Least One F508del Allele
    2023 74 citations Marcus Mall, Susanna A. McColley et al. American Journal of Respiratory and Critical Care Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Susanna A. McColley United States 38 5.0k 1.4k 855 846 512 116 6.6k
Mark Splaingard United States 30 2.7k 0.6× 811 0.6× 342 0.4× 623 0.7× 409 0.8× 88 4.3k
Frank J. Accurso United States 57 9.9k 2.0× 1.3k 0.9× 2.0k 2.3× 302 0.4× 1.8k 3.5× 191 12.5k
Eitan Kerem Israel 50 7.1k 1.4× 1.1k 0.8× 1.8k 2.1× 163 0.2× 1.4k 2.7× 263 10.0k
Peter Cole United Kingdom 43 2.5k 0.5× 1.8k 1.3× 604 0.7× 188 0.2× 547 1.1× 117 5.7k
Bruce K. Rubin United States 42 3.7k 0.7× 1.8k 1.3× 739 0.9× 201 0.2× 904 1.8× 174 6.4k
Mutsuo Yamaya Japan 44 2.7k 0.5× 1.6k 1.1× 2.0k 2.3× 270 0.3× 1.2k 2.3× 174 6.6k
K. De Boeck Belgium 49 7.0k 1.4× 1.2k 0.9× 1.4k 1.6× 71 0.1× 1.0k 2.0× 250 8.9k
D M Geddes United Kingdom 42 3.4k 0.7× 881 0.6× 995 1.2× 105 0.1× 616 1.2× 136 6.0k
Miguel Ángel Martínez‐García Spain 51 6.9k 1.4× 5.5k 3.9× 417 0.5× 3.1k 3.7× 1.2k 2.3× 307 10.3k
Richard B. Parad United States 34 3.5k 0.7× 224 0.2× 527 0.6× 482 0.6× 521 1.0× 102 5.4k

Countries citing papers authored by Susanna A. McColley

Since Specialization
Citations

This map shows the geographic impact of Susanna A. McColley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Susanna A. McColley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Susanna A. McColley more than expected).

Fields of papers citing papers by Susanna A. McColley

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Susanna A. McColley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Susanna A. McColley. The network helps show where Susanna A. McColley may publish in the future.

Co-authorship network of co-authors of Susanna A. McColley

This figure shows the co-authorship network connecting the top 25 collaborators of Susanna A. McColley. A scholar is included among the top collaborators of Susanna A. McColley based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Susanna A. McColley. Susanna A. McColley is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Heffernan, Marie E., et al.. (2025). The Newborn Screening Experience of Caregivers of Children With Cystic Fibrosis in the United States: A Cross‐Sectional Survey. Pediatric Pulmonology. 60(5). e71110–e71110. 1 indexed citations
2.
Wainwright, Claire, Susanna A. McColley, Paul McNally, et al.. (2025). Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Children ≥6 Years with Cystic Fibrosis and at Least One F508del Allele: A 192-Week, Phase 3, Open-Label Extension Study. American Journal of Respiratory and Critical Care Medicine. 211(10). 1915–1925. 1 indexed citations
3.
McGarry, Meghan E., et al.. (2022). Detection of disease‐causing CFTR variants in state newborn screening programs. Pediatric Pulmonology. 58(2). 465–474. 23 indexed citations
4.
Tzavelis, Andreas, et al.. (2021). P110 A soft, flexible, wearable device for cough detection in paediatric cystic fibrosis patients. Journal of Cystic Fibrosis. 20. S73–S73. 1 indexed citations
5.
McGarry, Meghan E. & Susanna A. McColley. (2021). Cystic fibrosis patients of minority race and ethnicity less likely eligible for CFTR modulators based on CFTR genotype. Pediatric Pulmonology. 56(6). 1496–1503. 98 indexed citations
6.
Martiniano, Stacey L., Alexander Elbert, Philip M. Farrell, et al.. (2021). Outcomes of infants born during the first 9 years of CF newborn screening in the United States: A retrospective Cystic Fibrosis Foundation Patient Registry cohort study. Pediatric Pulmonology. 56(12). 3758–3767. 22 indexed citations
7.
Savant, Adrienne P. & Susanna A. McColley. (2020). Cystic fibrosis year in review 2019: Section 1 CFTR modulators. Pediatric Pulmonology. 55(12). 3236–3242. 10 indexed citations
8.
Williams, Wadsworth A., Manu Jain, Theresa A. Laguna, & Susanna A. McColley. (2020). Preferences for disclosing adverse childhood experiences for children and adults with cystic fibrosis. Pediatric Pulmonology. 56(5). 921–927. 2 indexed citations
9.
McColley, Susanna A., et al.. (2020). Tolerance of 7% Hypertonic Saline in Pediatric Cystic Fibrosis Patients. Pediatric Allergy Immunology and Pulmonology. 33(2). 63–68. 1 indexed citations
10.
Savant, Adrienne P. & Susanna A. McColley. (2019). Cystic fibrosis year in review 2018, part 1. Pediatric Pulmonology. 54(8). 1117–1128. 7 indexed citations
11.
McNamara, John, Susanna A. McColley, Gautham Marigowda, et al.. (2019). Safety, pharmacokinetics, and pharmacodynamics of lumacaftor and ivacaftor combination therapy in children aged 2–5 years with cystic fibrosis homozygous for F508del-CFTR: an open-label phase 3 study. The Lancet Respiratory Medicine. 7(4). 325–335. 102 indexed citations
12.
Ideozu, Justin E., Xi Zhang, Susanna A. McColley, & Hara Levy. (2019). Transcriptome Profiling and Molecular Therapeutic Advances in Cystic Fibrosis: Recent Insights. Genes. 10(3). 180–180. 11 indexed citations
13.
Savant, Adrienne P. & Susanna A. McColley. (2019). Cystic fibrosis year in review 2018, part 2. Pediatric Pulmonology. 54(8). 1129–1140. 3 indexed citations
14.
Savant, Adrienne P. & Susanna A. McColley. (2017). Cystic fibrosis year in review 2016. Pediatric Pulmonology. 52(8). 1092–1102. 6 indexed citations
15.
Farrell, Philip M., Terry B. White, Clement L. Ren, et al.. (2017). Diagnosis of Cystic Fibrosis: Consensus Guidelines from the Cystic Fibrosis Foundation. Publisher. 3 indexed citations
16.
Rowe, Steven M., Susanna A. McColley, E. Rietschel, et al.. (2014). EFFECT OF 8 WEEKS OF LUMACAFTOR IN COMBINATION WITH IVACAFTOR IN PATIENTS WITH CF AND HETEROZYGOUS FOR THE F508DEL-CFTR MUTATION. Pediatric Pulmonology. 49. 306–306. 2 indexed citations
17.
Kern‐Goldberger, Andrew S., et al.. (2014). Disparities in Parental Health Literacy at a Pediatric Cystic Fibrosis Center. Pediatric Allergy Immunology and Pulmonology. 28(1). 55–59. 5 indexed citations
18.
Trapnell, Bruce C., Susanna A. McColley, Dana G. Kissner, et al.. (2011). Fosfomycin/Tobramycin for Inhalation in Patients with Cystic Fibrosis with Pseudomonas Airway Infection. American Journal of Respiratory and Critical Care Medicine. 185(2). 171–178. 103 indexed citations
19.
Seshadri, R., et al.. (2009). Increased prevalence of risk factors for morbidity and mortality in the US Hispanic CF population. Pediatric Pulmonology. 44(6). 594–601. 38 indexed citations
20.
McColley, Susanna A., Veronica Stellmach, Steven R. Boas, Manu Jain, & Susan E. Crawford. (2000). Serum Vascular Endothelial Growth Factor Is Elevated in Cystic Fibrosis and Decreases with Treatment of Acute Pulmonary Exacerbation. American Journal of Respiratory and Critical Care Medicine. 161(6). 1877–1880. 78 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mark Splaingard Breakdown of academic impact, for papers by Frank J. Accurso Breakdown of academic impact, for papers by Eitan Kerem Breakdown of academic impact, for papers by Peter Cole Breakdown of academic impact, for papers by Bruce K. Rubin Breakdown of academic impact, for papers by Mutsuo Yamaya Breakdown of academic impact, for papers by K. De Boeck Breakdown of academic impact, for papers by D M Geddes Breakdown of academic impact, for papers by Miguel Ángel Martínez‐García Breakdown of academic impact, for papers by Richard B. Parad
Rankless by CCL
2026